As volatility creeps into Editas Medicine, Inc. (NASDAQ:EDIT), investors need to pay close attention to to the factors affecting stock today as its shares are trading 13.09% or 3.03 points up from last closing price of $23.15, reaching $26.18 at last check. The EDIT share price has risen in 4 of the last 5 days and is down -9.53% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on solid volume too with far more shares changing hands than in a normal session. Trading activity as of this writing strengthened by 978,531 shares, and in total 1.512 million shares valued at $39.588 million were seen changing hands compared with 533600 shares valued at $12.353 million recorded at the previous session. You should take into consideration that a greater volume on higher prices causes bullish signal for the market. It shows the sentiment is in an uptrend and more and more traders want to enter in the EDIT stock.
Editas Medicine, Inc. (EDIT) shares have notched a 3-month decline of about -9.53%, but has still advanced 1.76% year to date. By comparison, the stock sank -17.56% over the past 12 months, while it jumped 17.33% over the 1 month. The company’s market cap is around $1.18B, with its short interest ratio standing at 13.92%.
In the current trading session for EDIT, the stock witnessed two major price actions, it rose to a high of $27.06 and was down as much as $23.34 at one point. The high recorded is very low when compared to their 52-week high which is $17.8. The 52-week high is now at -18.33 distance from current price. Their recent low of $32.46 represents a 48.94% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for EDIT is $46.71, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of Editas Medicine, Inc. earned $-2.47 per share in the trailing 12 months and has a P/E ratio of -10.6. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 21.97 and lower compared to the sector’s average of 32.25. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. EDIT also has P/S multiple of 92.45. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 2.62x.
EDIT‘s last price was up 13.59% as compared to the average trading price of 50 days recorded at $23.05 while enlarging the period to 200 trading days, the average closing price was $21.88. At present, there are 50.85 million in the total number of common shares owned by the public and among those 50.24 million shares have been available to trade. The percentage of shares being held by the company management was 0.1% while institutions stake was 81.7%. The company has generated negative returns on equity over the last 12 months (-56.5%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the EDIT stock, there is another set of technicals that should be looked into and considered. Its 23.84% gain from moving average of $21.14 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 2.46 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Editas Medicine, Inc. — 5 analysts rate the stock as a buy with another 0 rating it strong buy. There are 3 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $38 on shares of Editas Medicine, Inc. (NASDAQ:EDIT), which corresponds to 45.43% upside potential than its current market price of $26.18 and implies potential despite the recent advance in the price. However, their current target price has fallen from $38 a month ago and is down handily from the consensus target of $38.5 a quarter ago.